Long-term glioblastoma multiforme survivors: a population-based study

被引:105
作者
Scott, JN
Rewcastle, NB
Brasher, PMA
Fulton, D
Hagen, NA
MacKinnon, JA
Sutherland, G
Cairncross, JG
Forsyth, P
机构
[1] Tom Baker Canc Clin, Dept Med, Calgary, AB T2N 4N2, Canada
[2] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada
[3] Univ Calgary, Dept Pediat, Calgary, AB T2N 1N4, Canada
[4] Foothills Prov Gen Hosp, Dept Med, Calgary, AB T2N 2T9, Canada
[5] Univ Calgary, Dept Pathol & Clin Neurosci, Calgary, AB, Canada
[6] Univ Calgary, Dept Epidemiol Prevent & Screening, Alberta Canc Board & Community Hlth Sci, Calgary, AB, Canada
[7] Cross Canc Inst, Dept Radiat Oncol, Edmonton, AB T6G 1Z2, Canada
[8] Univ Alberta, Dept Med Neurol, Edmonton, AB, Canada
[9] Univ Calgary, Tom Baker Canc Ctr, Dept Radiat Oncol, Calgary, AB, Canada
[10] Univ Western Ontario, Dept Clin Neurol Sci, London, ON N6A 3K7, Canada
[11] Univ Western Ontario, Dept Oncol, London, ON N6A 3K7, Canada
[12] London Reg Canc Ctr, London, ON N6A 4L6, Canada
关键词
D O I
10.1017/S0317167100034016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Long-term glioblastoma multiforme survivors (LTGBMS) are uncommon. The frequency which these occur in an unselected population and factors which produce these unusually long survivors are unknown. Objectives: To determine in a population-based study 1) the frequency of LTGBMS in a population and 2) identify which patient, treatment or tumor characteristics would predict which glioblastoma (GBM) patient would become a LTGBMS, Methods: The Alberta Cancer Registry was used to identify all patients diagnosed with GEM in southern Alberta between 1/1/75 - 12/31/91, Patient charts were reviewed and histology re-examined by a blinded neuropathologist, LTGBMS were defined as (GBM patients surviving greater than or equal to 3 years after diagnosis. Each LTGBMS was compared to three age-, gender-, and year of diagnosis-matched controls to compare patient, treatment, and tumor factors to GEM patients without long-term survival. Results: There were 279 GBMs diagnosed in the study period. Five (1.8%) survived greater than or equal to three years (range, 3.2-15.8 years). Seven additional long-term survivors, who carried a diagnosis of GEM, were excluded after neuropathologic review; the most common revised diagnosis was malignant oligodendroglioma, LTGBMS (avg,age = 45 years) were significantly younger when compared to all GEM patients (avg. age = 59 years, p = 0.0001) diagnosed in the study period. LTGBMS had a higher KPS at diagnosis (p = 0.001) compared to controls, Tumors from LTGBMS tended to have fewer mitoses and a lower Ki-67 cellular proliferative index compared to controls. Radiation-induced dementia was common and disabling in LTGBMS. Conclusions: These data highlight the dismal prognosis for GEM patients who have both a short median survival and very small chance (1.8%) of long-term survival. The LTGBMS were younger, had a higher performance status, and their tumors tended to proliferate less rapidly than control GEM patients. When long-term survival does occur it is often accompanied by severe treatment-induced dementia.
引用
收藏
页码:197 / 201
页数:5
相关论文
共 28 条
[1]   COGNITIVE-FUNCTIONING IN LONG-TERM SURVIVORS OF HIGH-GRADE GLIOMA [J].
ARCHIBALD, YM ;
LUNN, D ;
RUTTAN, LA ;
MACDONALD, DR ;
DELMAESTRO, RF ;
BARR, HWK ;
PEXMAN, JHW ;
FISHER, BJ ;
GASPAR, LE ;
CAIRNCROSS, JG .
JOURNAL OF NEUROSURGERY, 1994, 80 (02) :247-253
[2]  
Balmaceda Casilda, 1996, Neurology, V46, pA451
[3]  
Byar DP, 1983, ONCOLOGY NERVOUS SYS, P379
[4]   CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA [J].
CAIRNCROSS, G ;
MACDONALD, D ;
LUDWIN, S ;
LEE, D ;
CASCINO, T ;
BUCKNER, J ;
FULTON, D ;
DROPCHO, E ;
STEWART, D ;
SCHOLD, C ;
WAINMAN, N ;
EISENHAUER, E .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2013-2021
[5]   LONG-TERM SURVIVAL IN PATIENTS WITH GLIOBLASTOMA-MULTIFORME [J].
CHANDLER, KL ;
PRADOS, MD ;
MALEC, M ;
WILSON, CB ;
SALEMAN, M ;
BLACK, PM .
NEUROSURGERY, 1993, 32 (05) :716-720
[6]  
DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO
[7]  
2-T
[8]   EPIDERMAL GROWTH-FACTOR RECEPTOR ACTIVITY AND CLINICAL OUTCOME IN GLIOBLASTOMA AND MENINGIOMA [J].
DORWARD, NL ;
HAWKINS, RA ;
WHITTLE, IR .
BRITISH JOURNAL OF NEUROSURGERY, 1993, 7 (02) :197-199
[9]   LONG-TERM POSTOPERATIVE SURVIVAL IN 2 CASES OF GLIOBLASTOMA MULTIFORME [J].
ELVIDGE, AR ;
BARONE, BM .
JOURNAL OF NEUROSURGERY, 1965, 22 (04) :382-&
[10]  
FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO